Sign inCreate account

Report workspace tools

NCT04803864UNKNOWNanonymous

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Roxadustat in Patients With Acute ST Elevation Myocardial Infarction

Sponsor

Source record

Ruijin Hospital

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Acute ST Elevation Myocardial Infarction

Indication / condition

AI-normalized

ST Elevation Myocardial Infarction

Intervention

Source record

Roxadustat

Source & freshness

Source record

NCT ID

NCT04803864

Original source

ClinicalTrials.gov

Source last updated

Sep 01, 2021

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04803864

Title

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Roxadustat in Patients With Acute ST Elevation Myocardial Infarction

Sponsor

Ruijin Hospital

Status

UNKNOWN

Phase

Phase 2

Condition raw

ST Elevation Myocardial Infarction

Condition normalized

ST Elevation Myocardial Infarction

Modality raw

ST Elevation Myocardial Infarction

Modality normalized

small molecule

Target raw

Acute ST Elevation Myocardial Infarction

Target normalized

Acute ST Elevation Myocardial Infarction

Interventions

Roxadustat

Public preview

Source record

This clinical trial evaluates the safety and efficacy of Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with acute ST elevation myocardial infarction. The study is conducted by Ruijin Hospital and aims to address the poor prognosis associated with this condition despite standard treatments.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Roxadustat in Patients With Acute ST Elevation Myocardial Infarction

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04803864

Status

UNKNOWN

Phase

Phase 2

Sponsor

Ruijin Hospital

Executive brief

Investment-Ready Snapshot

This clinical trial evaluates the safety and efficacy of Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with acute ST elevation myocardial infarction. The study is conducted by Ruijin Hospital and aims to address the poor prognosis associated with this condition despite standard treatments.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 01, 2021
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04803864

Indication

ST Elevation Myocardial Infarction

Modality

small molecule

Target

Acute ST Elevation Myocardial Infarction

Intervention

Roxadustat

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.